Efficacy and safety results from the TOPAZ Phase 2 trial evaluating apitegromab, a  muscle-directed therapy for spinal muscular atrophy (SMA) being developed by Scholar Rock, are expected by June, the company announced. “2020 was a transformative year for Scholar Rock with … positive interim data from the TOPAZ trial providing initial proof-of-concept of apitegromab’s potential in SMA,” Tony Kingsley, president and CEO of Scholar Rock, said in a press release. “In 2021, we will further elucidate…

You must be logged in to read/download the full post.